<html>
<head>
<style><!--
.hmmessage P
{
margin:0px;
padding:0px
}
body.hmmessage
{
font-size: 10pt;
font-family:Tahoma
}
--></style>
</head>
<body class='hmmessage'><div dir='ltr'>
<div><font class="Apple-style-span" face="Tahoma" size="2">CaniLeish<span class="Apple-style-span" style="background-color: rgb(255, 255, 255); ">®</span>:</font></div><div><font class="Apple-style-span" face="Tahoma" size="2"><br></font></div><div><font class="Apple-style-span" size="2" face="Tahoma"> The European Commission granted a marketing authorisation valid throughout the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.</font></div><div><font class="Apple-style-span" size="2" face="Tahoma"><br></font></div><div><font class="Apple-style-span" size="2" face="Tahoma"> This vaccine, <span class="Apple-style-span" style="background-color: rgb(255, 255, 255); ">CaniLeish®, will initially be launched in Portugal at the end of the first half of 2011. This will be followed rapidly by launches in other countries in the endemic area: Spain, France, Greece and Italy (not in chronological order). This roll-out takes account of the geographical prevalence of the disease and the time required to build vaccine production up to full capacity. The launch in Northern European countries from where there is a flow of summer visitors to the endemic area will be part of a second phase.</span></font></div><div><font class="Apple-style-span" size="2" face="Tahoma"><span class="Apple-style-span" style="background-color: rgb(255, 255, 255); "><br></span></font></div><div><font class="Apple-style-span" size="2" face="Tahoma"><span class="Apple-style-span" style="background-color: rgb(255, 255, 255); "> The basis of this vaccine are excreted proteins plus a saponin adjuvant purified from Quil-A. Its efficacy was determined in a 2 year open field trial.</span></font></div><div><font class="Apple-style-span" size="2" face="Tahoma"><span class="Apple-style-span" style="background-color: rgb(255, 255, 255); "><br></span></font></div><div><font class="Apple-style-span" size="2" face="Tahoma"><span class="Apple-style-span" style="background-color: rgb(255, 255, 255); "> The vaccine is given to dogs as three injections, three weeks apart, under the skin. The first injection can be given from six months of age, the second injection is given three weeks later and the third three weeks from the second one. Afterward a single ‘booster’ should be given every year to maintain protection.</span></font></div> </div></body>
</html>